Bitterroot Bio nabs $145M Series A with a plan to tackle challenging cancer target for heart medicines
The founders of cancer biotech Forty Seven had initially envisioned that the company would also work on developing heart drugs that cut down inflammation. Before it could really get started on that front, however, the company was bought by Gilead for $4.9 billion.
But Forty Seven’s founders, including Stanford professor of cardiovascular medicine Nick Leeper and stem cell pioneer Irv Weissman, kept working on that science, publishing an article in the New England Journal of Medicine in 2021 demonstrating how Forty Seven’s lymphoma drug candidate magrolimab also tamped down on blood vessel inflammation.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.